Two highly respected physicians from Beloit Memorial Hospital in Wisconsin recently uploaded the results of their research for the world to review. A very well respected researcher associated with the U.S. government suggested to the TrialSite to review their work. These physicians articulate that Famotidine, a histamine H2 receptor antagonist/inverse agonist commonly used to treat mast cell activation syndrome (symptoms include anaphylaxis) reduced COVID-19 mortality in one hospital-based retrospective study. The Wisconsin-based providers introduce Prostaglandin E2 (PGE2), a naturally occurring prostaglandin used as a medication, controls various characteristic and adaptive immune responses such as mass cell activation. The providers point out a prospective study involving patients hospitalized for COVID-19 where the administration of the COX-2 antagonist celecoxib not only inhibited PGE2 levels but also prevented clinical degradation and was also connected with improved CT-chest improvement. Hence the Beloit Memorial Hospital providers put forth their hypothesis: adjuvant therapy with a combination of celecoxib with famotidine could very well improve outcomes in hospitalized COVID-19 patients.
The Study Methodology
Actually a consecutive case series led at a single center involving 14 COVID-19 hospitalized patients that were treated with high dose of famotidine in combination with celecoxib as adjuvant therapy. The doctors administered oral famotidine (80 mg four times per day—QID) and oral celecoxib (200 mg twice daily (BID) after a 400 mg loading dose. The doctors looked toward key metrics including time to discharge, changes in supplemental oxygen requirements, CT-chest findings, and laboratory changes in peripheral blood lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin, lymphocyte levels and D-dimer.
The Beloit Memorial Hospital pair reported that all of the patients in the series survived hospitalized COVID-19 and were discharged without oxygen with a median of 5 days (range 1-14 days). The providers also observed noticeable improvements in supplemental oxygen requirements, ground-glass CT findings, LDH, ferritin, CRP, D-dimer and lymphocyte levels.
Call for Randomized Controlled Trial
The physicians believe the results justify the investment in a randomized controlled trial to investigate the hypothesis that high dose famotidine with celecoxib could possibly prevent clinical deterioration in adult hospitalized COVID-19 patients.
Famotidine & the Cold Spring Laboratory Case Series
In at least one observational study sponsored by Cold Spring Harbor Laboratory, the prominent New York-based laboratory and some well-respected physicians from Northwell Health Cancer Institute conducted a retrospective case series targeting ten (10) non-hospitalized patients with COVID-19. High doses of famotidine were not only well tolerated by led to improved patient-reported outcomes. This study doesn’t provide any clinical evidence but does represent at least some real world data to consider. Note, there is some controversy associated with famotidine and federal dollars invested in a study at Northwell Health. However that wasn’t associated with the Cold Spring or Beloit Memorial Hospital-based activity.
About Beloit Memorial Hospital
Beloit Health System is an independent community health system serving northern Illinois and southern Wisconsin. The health system offers world-class facilities and services to improve the overall health of the communities they serve with cornerstones for quality, engagement, integrity and patient satisfaction.
Call to Action: Follow up and read the entire case series report. TrialSite has been informed by very knowledgeable resources that these two doctors are on to an important investigation. See the link.